Funding allows Stem Cell to finish merger with South Korean firm

03/17/2009 | American City Business Journals

Stem Cell Therapy International said it has secured short-term funding to finalize its merger with HistoStem, a South Korean firm that manages a cord blood and stem cell bank, to create a firm called AmStem International. Under the merger, AmStem is expected to bring to the U.S. adult stem cells from Asia for use in clinical studies and treatments.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA